Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib.
about
Alterations of the intracellular peptidome in response to the proteasome inhibitor bortezomibBeyond picomolar affinities: quantitative aspects of noncovalent and covalent binding of drugs to proteinsIncorporation of Non-natural Amino Acids Improves Cell Permeability and Potency of Specific Inhibitors of Proteasome Trypsin-like SitesTouch and go: nuclear proteolysis in the regulation of metabolic genes and cancerMechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone RemodelingProteasome inhibitors alter levels of intracellular peptides in HEK293T and SH-SY5Y cellsProteasomal chymotrypsin-like peptidase activity is required for essential functions of human monocyte-derived dendritic cells.Proteasome inhibition suppresses essential immune functions of human CD4+ T cells.Targeting the UPS as therapy in multiple myeloma.Proteasome inhibitors in glioblastomaEffects of a novel proteasome inhibitor BU-32 on multiple myeloma cells.Strategies for discovering and derisking covalent, irreversible enzyme inhibitors.Alternative Ii-independent antigen-processing pathway in leukemic blasts involves TAP-dependent peptide loading of HLA class II complexes.Muscle wasting in aged, sarcopenic rats is associated with enhanced activity of the ubiquitin proteasome pathway.Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib.Fulvestrant-induced cell death and proteasomal degradation of estrogen receptor α protein in MCF-7 cells require the CSK c-Src tyrosine kinase.Gold(III)-dithiocarbamato peptidomimetics in the forefront of the targeted anticancer therapy: preclinical studies against human breast neoplasia.Multicolor monitoring of the proteasome's catalytic signature.Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy.Fundamental reaction pathway and free energy profile of proteasome inhibition by syringolin A (SylA).Anticancer Effect of a Novel Proteasome Inhibitor, YSY01A, via G2/M Arrest in PC-3M Cells in vitro and in vivo.Subunit specific inhibitors of proteasomes and their potential for immunomodulationThe novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.The proteasomal and apoptotic phenotype determine bortezomib sensitivity of non-small cell lung cancer cells.Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myelomaCombination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myelomaNew approaches for dissecting protease functions to improve probe development and drug discoveryCompensatory increase in USP14 activity accompanies impaired proteasomal proteolysis during agingUbiquitin proteasome system as a pharmacological target in neurodegeneration.A novel proteasome inhibitor NPI-0052 as an anticancer therapy.Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance.Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08).Application of activity-based probes to the study of enzymes involved in cancer progression.Preclinical studies of novel targeted therapies.Targeting apoptosis in solid tumors: the role of bortezomib from preclinical to clinical evidence.Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trialsSequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasoneMeasuring activity in the ubiquitin-proteasome system: from large scale discoveries to single cells analysisActivity-based imaging probes of the proteasome.Proteasomal regulation of caspase-8 in cancer cell apoptosis
P2860
Q21090814-2970407C-BC4E-4381-9AF8-76E4F2DBBB17Q24649147-2BB63DA5-5053-465B-BA91-E2E6A2FB9273Q27675903-BFEF8324-7D2F-4B8C-B686-D7DA985545F9Q28068146-A6CE10F3-6B7C-4852-B208-6C016012B7A6Q28082335-61AA8BDD-16BF-4153-819E-740286F8D300Q28541433-0C79B72E-2669-4B57-93B7-4FEE2BB86474Q33262643-2B820B03-D86D-46C6-AE9E-30DE168E1745Q33316357-29359D5A-5C3D-42CC-B447-0943F8C1F7E8Q33384287-561C0834-C71E-450A-A3F4-F5223CA636CEQ33598931-13BC9D8C-0DE4-42CA-91B3-AA391F933E7EQ33675494-4380C90C-0EB8-4667-8DEC-2CCE8685DE22Q34023143-54ED83C7-6209-499F-8714-AAD5E123FC05Q34155000-6FA0EA68-AF88-4955-98CC-207B67035BCEQ34400761-721E84D8-55C7-4B06-9384-225047116DB5Q34608271-A3DD0596-5F71-4662-9AAE-17490B4C3823Q34674316-55AC98B2-BFF2-4425-A78D-F9462995E998Q35083349-AEB4181A-0D8F-4E31-93C9-BE98B2840F3AQ35121111-D41932C9-55CA-4A12-8AD4-180573B85E2CQ35408665-28AB4C49-FB4C-4457-A9C4-25A37C7426C7Q35756052-9585FFD0-9307-4780-AB55-573787231D36Q35856827-F2266929-7A40-4AAB-B942-886A753FFCCEQ36042649-ED00DF55-DE3E-4529-80DA-8537B6C21092Q36115692-13A97DC7-5243-4012-94F4-AE14868A362CQ36372909-65402326-54A9-4BEE-9AA2-0444E3F2EA82Q36384889-26C0B385-40D8-4FE8-B6E0-28FA3B4BAB03Q36407209-EF0047DA-4A5D-4009-AF88-4B925685C0F3Q36442058-190F4D3B-1537-4887-B727-D51DE4726D22Q36572619-4ED239DA-ACC5-40CD-BC69-42447E5CBB09Q36607342-5675CE09-B30C-4462-9277-CF49B5B5DE35Q36626591-AC0A8772-B3EE-4AE4-B68F-0AE54E4A5EC4Q36736534-B8E7CFE7-237B-47B5-B941-022A6FBB95AAQ36750467-92ED153E-4888-4913-8981-04BE90A5A150Q36775132-61BAB31F-1DC3-408E-832A-D626E0B36BFBQ36998210-60B65471-B919-4987-B288-8BC0FB8367C7Q37004739-1C1F57C2-7EB5-4E24-993A-E5B5625286C9Q37017342-6D65B059-F993-4720-BC3F-0767732B10A6Q37132862-B22E445F-A251-4642-923C-01D94B467486Q37136216-DEC31F03-A9D7-4107-B1A1-942B91C328AEQ37136304-F694544F-C69E-4A8D-B140-19BADD3EB755Q37146270-4AEE97CF-F0B3-4E6F-AB28-EB04CCD1AA68
P2860
Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Activity probe for in vivo pro ...... oteasome inhibitor bortezomib.
@en
type
label
Activity probe for in vivo pro ...... oteasome inhibitor bortezomib.
@en
prefLabel
Activity probe for in vivo pro ...... oteasome inhibitor bortezomib.
@en
P2093
P50
P356
P1433
P1476
Activity probe for in vivo pro ...... oteasome inhibitor bortezomib.
@en
P2093
Celia R Berkers
Eben Lichtman
Edda Fiebiger
Hidde L Ploegh
Kenneth C Anderson
Paul J Galardy
P2888
P304
P356
10.1038/NMETH759
P577
2005-04-21T00:00:00Z
P6179
1025220766